Boothbay Fund Management’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-79,587
| Closed | -$17.6M | – | 2102 |
|
|
2025
Q4 | $17.6M | Sell |
79,587
-22,277
| -22% | -$3.6M | 0.26% | 56 |
|
|
2025
Q3 | $9.75M | Sell |
101,864
-55,962
| -35% | -$3.57M | 0.14% | 163 |
|
|
2025
Q2 | $7.69M | Buy |
157,826
+78,745
| +100% | +$1.89M | 0.15% | 184 |
|
|
2025
Q1 | $1.7M | Buy |
79,081
+63,480
| +407% | +$1.41M | 0.04% | 466 |
|
|
2024
Q4 | $419K | Buy |
+15,601
| New | +$253K | 0.01% | 944 |
|
|
2019
Q3 | – | Sell |
-1,775
| Closed | -$60K | – | 776 |
|
|
2019
Q2 | $60K | Hold |
1,775
| – | – | 0.01% | 680 |
|
|
2019
Q1 | $94K | Hold |
1,775
| – | – | 0.01% | 663 |
|
|
2018
Q4 | $83K | Sell |
1,775
-385
| -18% | -$27.5K | 0.01% | 567 |
|
|
2018
Q3 | $190K | Hold |
2,160
| – | – | 0.02% | 662 |
|
|
2018
Q2 | $225K | Hold |
2,160
| – | – | 0.02% | 581 |
|
|
2018
Q1 | $173K | Sell |
2,160
-570
| -21% | -$77.9K | 0.02% | 621 |
|
|
2017
Q4 | $371K | Buy |
2,730
+1,315
| +93% | +$199K | 0.05% | 360 |
|
|
2017
Q3 | $229K | Sell |
1,415
-417
| -23% | -$59.3K | 0.04% | 468 |
|
|
2017
Q2 | $275K | Buy |
+1,832
| New | +$253K | 0.06% | 432 |
|
Boothbay Fund Management's CDTX Position: Q1 2026 in Review
Boothbay Fund Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 79,587 shares — an estimated $17.6M sold.
Boothbay Fund Management first reported a position in CDTX in Q2 2017 and held it in 14 quarters. The position peaked at $17.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Boothbay Fund Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Boothbay Fund Management sold 79,587 Cidara Therapeutics shares in Q1 2026, an estimated $17.6M.
- Boothbay Fund Management first reported a position in Cidara Therapeutics in Q2 2017 and held it in 14 quarters.
- Boothbay Fund Management's Cidara Therapeutics position peaked at $17.6M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.